Mosaic Therapeutics appoints Thomas Fuchs as chief executive

Mosaic Therapeutics has named Thomas Fuchs as chief executive to lead the Cambridge, UK-based oncology biotech through its transition into clinical development and a planned series B fundraising round. He succeeds interim chief executive Magda Jonikas, who will remain on the board as a non-executive director.

Mr Fuchs brings more than 25 years of experience in oncology drug development and commercialization. He most recently served as chief executive at Cimeio Therapeutics, where he oversaw a $50 million series A raise and a strategic collaboration with Japan’s Kyowa Kirin (TSE: 4151). Earlier, he spent 15 years at Roche (ROG: SIX), heading its global haematology franchise, which generated more than $8 billion in annual sales.

Chairman Edward Hodgkin said the appointment would strengthen Mosaic’s leadership and help position the company as a future category leader in precision oncology. Mr Fuchs said he was eager to advance the company’s pipeline and fundraising plans, aiming to bring new combination therapies to cancer patients.